Pancreatic Cancer Research

ResearcherMayo ClinicNo recent work listed

George P. Kim

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 6 November 2026

Matched on OpenAlex author ID A5082512772. Sources: ClinicalTrials.gov.

Their work

Papers
8 (first author 1, last author 0)
Trials
3
Grants
0
Labs led
0
Collaborators
37
Papers, trials and grants by year

2005: 1 trial · 2006: none · 2007: none · 2008: none · 2009: 2 trials · 2010: none · 2011: none · 2012: 1 paper · 2013: none · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper

Papers 8

  1. N064A (Alliance): Phase II Study of Panitumumab, Chemotherapy, and External Beam Radiation in Patients with Locally Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1093/oncolo/oyac002↗
  2. Real-world outcomes associated with liposomal irinotecan dose reductions in metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.2217/fon-2020-0902↗
  3. Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. Co-author DOI 10.1016/j.pan.2019.11.011↗
  4. A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adeno… Co-author DOI 10.1634/theoncologist.2018-0878↗
  5. Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel p… Co-author DOI 10.1080/17512433.2017.1302330↗
  6. Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study. First author DOI 10.1007/s10637-015-0246-2↗
  7. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-con… Co-author DOI 10.1097/mpa.0000000000000095↗
  8. A phase 2 trial of ixabepilone plus cetuximab in first-line treatment of metastatic pancreatic cancer. Co-author PMID 23112883↗

Trials 3

  1. Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer Study chair NCT00550836↗
  2. Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery Study chair NCT00601627↗
  3. Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer Study chair NCT00112528↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Thorvardur Ragnar Halfdanarson · 2 shared papers, 2019–2022 · strength 0.27
  2. Steven R. Alberts · 2 shared papers, 2019–2022 · strength 0.27
  3. Michael G. Haddock · 1 shared paper, 2022 · strength 0.17
  4. Thomas C. Smyrk · 2 shared papers, 2019–2020 · strength 0.17
  5. Paul C. Cockrum · 1 shared paper, 2021 · strength 0.16
  6. Bruce Belanger · 1 shared paper, 2021 · strength 0.16
  7. Laith I. Abushahin · 1 shared paper, 2021 · strength 0.16
  8. Charles Erlichman · 2 shared papers, 2015–2020 · strength 0.14
  9. Robert R. McWilliams · 2 shared papers, 2015–2020 · strength 0.14
  10. Tanios Bekaii‐Saab · 2 shared papers, 2014–2020 · strength 0.11
  11. Kathy W. Belk · 1 shared paper, 2017 · strength 0.09
  12. Manish Patel · 1 shared paper, 2017 · strength 0.09
  13. Wilma Lingle · 1 shared paper, 2020 · strength 0.08
  14. Mitesh J. Borad · 1 shared paper, 2020 · strength 0.08
  15. Ezequiel J. Tolosa · 1 shared paper, 2020 · strength 0.08
  16. Aminah Jatoi · 1 shared paper, 2020 · strength 0.08
  17. Angela L. McCleary‐Wheeler · 1 shared paper, 2020 · strength 0.08
  18. Axel F. Grothey · 1 shared paper, 2020 · strength 0.08
  19. Julian R. Molina · 1 shared paper, 2020 · strength 0.08
  20. Ryan Michael Carr · 1 shared paper, 2020 · strength 0.08
  21. Henry Clement Pitot · 1 shared paper, 2020 · strength 0.08
  22. Mien‐Chie Hung · 1 shared paper, 2020 · strength 0.08
  23. Martín E. Fernández-Zapico · 1 shared paper, 2020 · strength 0.08
  24. Katrina Sophia Pedersen · 1 shared paper, 2015 · strength 0.06
  25. Andrea Wang‐Gillam · 1 shared paper, 2015 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.